Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 1370368, 8 pages
Research Article

Isolation and Biological Evaluation of Prenylated Flavonoids from Maclura pomifera

1National Center for Natural Products Research, University of Mississippi, University, MS 38677, USA
2South-Kazakhstan State Pharmaceutical Academy, Al-Farabi Square, Shymkent 160019, Kazakhstan
3Department of Chemistry of Natural Compounds, National Research Center, Dokki, Cairo 12622, Egypt
4Kazakh National Medical University, Almaty 050000, Kazakhstan
5Department of Biomolecular Science, University of Mississippi, University, MS 38677, USA

Correspondence should be addressed to Samir A. Ross; ude.ssimelo@ssors

Received 21 September 2017; Accepted 9 December 2017; Published 14 January 2018

Academic Editor: Armando Zarrelli

Copyright © 2018 Yerkebulan Orazbekov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Phytochemical analysis of the ethanolic extract of Maclura pomifera fruits yielded four new compounds (IIV) along with eleven known compounds (VXV). The crude extract exhibited significant activity towards cannabinoid receptors (CB1: 103.4% displacement; CB2: 68.8% displacement) and possibly allosteric interaction with and opioid receptors (−49.7 and −53.8% displacement, resp.). Compound I was found to be possibly allosteric for and opioid receptors (−88.4 and −27.2% displacement, resp.) and showed moderate activity (60.5% displacement) towards CB1 receptor. Compound II exhibited moderate activity towards cannabinoid receptors CB1 and CB2 (47.9 and 42.3% displacement, resp.). The known compounds (VVIII) exhibited prominent activity towards cannabinoid receptors: pomiferin (V) (IC50 of 2.110 and 1.318 μM for CB1 and CB2, resp.), auriculasin (VI) (IC50 of 8.923 μM for CB1), warangalone (VII) (IC50 of 1.670 and 4.438 μM for CB1 and CB2, resp.), and osajin (VIII) (IC50 of 3.859 and 7.646 μM for CB1 and CB2, resp.). The isolated compounds were also tested for inhibition of human monoamine oxidase-A and monoamine oxidase-B enzymes activities, where all the tested compounds showed fewer inhibitory effects on MAO-A compared to MAO-B activities: auriculasin (VI) (IC50 of 1.91 and 45.98 μM for MAO-B and MAO-A, resp.).